The US Food and Drug Administration (FDA) has approved Ixchiq, French specialty vaccines developer Valneva’s (Nasdaq: VALN) single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
Valneva’s shares jumped 11.4% to 6.93 euros following the announcement. The company said it has plans to begin commercializing the vaccine in the USA, early next year.
Valneva’s chikungunya vaccine is expected to be a blockbuster drug in the field, with GlobalData forecasting $248 million in global sales for the vaccine in 2029.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze